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Sllmmal'y 
As observed for many types of cancers,  heritable variants of ultraviolet light-induced tumors 
often grow more aggressively than the parental tumors. The aggressive growth of some variants 
is due to the loss of a T  cell-recognized tumor-specific antigen; however,  other variants retain 
such antigens. We have analyzed an antigen retention variant and found that the variant tumor 
cells grow at the same rate as the parental tumor cells in vitro, but grew more rapidly than 
the parental cells in the T  cell-deficient host. The growth of the variant cells was stimulated 
in vitro by factors released from tumor-induced leukocytes and by several defined growth factors. 
In addition, the variant cancer cells actually attracted more leukocytes in vitro than the parental 
cells. Furthermore, elimination of granulocytes in vivo in nude mice by a specific antigranulocyte 
antibody inhibited the growth of the variant cancer, indicating that this tumor requires granulocytes 
for rapid growth. 
T 
he appearance of heritable variants with increased malig- 
nant potential is one of the hallmarks of cancer. Such 
variants fall into one or more of three broad categories:  those 
that have acquired resistance  to inhibition by host defenses 
or chemotherapy, those that more effectively  invade or metasta- 
size, and those that acquire a faster growth rate. Determining 
the mechanisms that account for escape of variants from host 
control may help in developing new therapeutic approaches 
tailored to interfere with particular mechanisms of tumor 
progression. 
UV light-induced cancers, when transplanted into normal 
syngeneic hosts, are usually rejected after a period of initial 
growth (1). Rejection depends on CD8 + CTL specific for 
unique antigens expressed by the cancer cells (2, 3).  Occa- 
sionally these "regressor" (RE) tumors give rise to variants 
that grow progressively and kill normal hosts. Some "pro- 
gressor" (PRO) variants have lost T cell-recognized unique 
tumor-specific antigens. More commonly, however, such an- 
tigens are retained (3). We have compared the growth of such 
an antigen retention PRO with that of the parental RE in 
vitro and in vivo. We found that the parental and the variant 
tumors,  designated  4102-RE  and  4102-PRO,  differ 
significantly in the rate of growth in mice devoid of func- 
tional T cells. We show that 4102-PRO requires host granu- 
locytes for rapid growth and that elimination of the host cells 
by an antigranulocyte antibody reduces tumor growth. 
Materials  and Methods 
Mice and  Tumors.  Athymic nu/nu mice (from the  National 
Cancer Institute, Frederick  Cancer Research Facility,  Frederick, MD) 
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were used for all experiments except for those using anti-NKl.1, 
where B6CByF1/J nu/nu mice (which express the NKI.1 marker 
on NK cells) from The Jackson Laboratory (Bar Harbor, ME) were 
used. The 4102 RE tumor was induced  by UV light at the LaRabida- 
University of Chicago Institute, adapted to culture in MEM and 
10% FCS (CMEM), and maintained as described  (2, 3). The tumor 
is called a regressor because it is rejected by normal euthymic mice 
even without prior immunization (2), but the tumor grows regu- 
larly in nude mice and kills such mice. Unlike the parental 4102- 
RE tumor, the 4102-PRO variant when transplanted into euthymic 
syngeneic  mice grows progressively  to kill. All tumor cell lines were 
tested regularly for mycoplasma  contamination by staining with 
HOECHST 33258 and examination of a fluorescence  microscope. 
Antibodies.  RB6-8C5  (anti-Gr-1) was a gift of Dr. Robert L. 
Coffman (DNAX Research Institute, Palo Alto, CA). GK1.5,  which 
recognizes the CD4 marker on a subset of T cells (4), was used 
as an IgG2b isotype control in nude mice, which lack such T cells. 
Anti-NKl.1  was a gift of Dr. Paul Leibson (Mayo Clinic, Roch- 
ester, MN). The efficiency  of the anti-Gr-1 antibody for depleting 
neutrophils was determined by examining peripheral blood smears 
and smears of peritoneal exudate cells prepared by a cytospin cen- 
trifuge (Shandon Inc., Pittsburgh,  PA). 
Tumor Growth In Viva  5 x  106 tumor cells were injected sub- 
cutaneously into the flanks of three to four athymic nude mice. 
Tumor growth was measured every 3-4 d with a caliper. Size in 
cm  3 was calculated as (abc)/2 where a,  b,  and c are three or- 
thogonal diameters. This formula is derived from the formula for 
the volume of an ellipsoid =  II abc 
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Recovery of Cells  from the Peritoneal Cavity.  Peritoneal exudate 
cells (PEC) were harvested from nude mice that were either naive 
(N-PEC) or that received an i.p. injection 3 d earlier of 2 ml of 
aged thioglycolate medium  (I-PEC) (Difco Laboratories, Inc., 
J. Exp. Med. ￿9  The Rockefeller  University  Press ￿9 0022-1007/95/01/0435/06 $2.00 
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(T-PEC). PEC (containing tumor cells or not) were removed after 
3 d  by injecting 5 ml of sterile PBS witha 5-ml syringe and 20- 
gauge needle, massaging the abdomen, and then aspirating the fluid. 
The recovered cells were sedimented at 225 g for 5 min, resuspended 
in 12 ml CMEM,  and put into culture dishes as described below. 
Assay for Quantifying  Viable Cells.  To assess cell growth,  20 
#1 of 3-(4,5-dimethyhhiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) solution (5 mg/ml) was added to each culture containing 
100 #1 of medium (after removal of 100 #1 of the original medium) 
for 4-6 h, followed by 100 #1 of 10% SDS plus 0.01 N  HC1. OD 
were read on an ELISA reader at 570  nm,  subtracting the back- 
ground  at 650  nm. 
Chemoattraction Assay.  Medium conditioned for 24 h by 1.5  x 
106  tumor  cells in  10  ml of CMEM  was  added to  two bottom 
wells of modified Boyden chambers (NeuroProbe, Cabin John, MD). 
2  x  10  s thioglycolate-elicited I-PEC were added to the top cham- 
ber in a volume of 200 #1.  The I-PEC were suspended in either 
fresh CMEM  (to test for directional movement)  or in the same 
tumor cell-conditioned media as in the lower chamber (to distin- 
guish from increased random movement). The top chambers with 
the I-PEC were separated from the lower chambers containing tumor 
cell-conditioned media by a polycarbonate filter with a pore size 
of 5 #m  (Neuro Probe).  Chambers  were incubated for 90 min. 
Unmigrated cells were washed off the tops of filters by aspirating 
the 200 #1 of medium that contained the I-PEC, wiping the filter 
with  a  Q-tip,  adding  distilled water  with  a  squirt  bottle,  and 
repeating three times.  The  filters were stained by dipping them 
into a staining solution (Diff-Quick;  Baxter, McGaw Park,  IL). 
Cells that had migrated through the filter pores were counted using 
a magnification of 400, and the average of six fields from the dupli- 
cate filters  _+  SEM was plotted. 
component(s). The growth of PRO but not RE cells was 
stimulated in culture by T-PEC from nude mice. The stimu- 
lation was most likely due to a soluble factor since similar 
effects were observed when T-PEC and tumor cells were sepa- 
rated by a filter in transwell plates (Fig. 2, left). Growth factors 
that have been shown to stimulate some malignant cells (5) 
were added to tumor cells in vitro. These included TGF-/$, 
platelet-derived growth factor (PDGF), basic fibroblast growth 
factor (bFGF), and epidermal growth factor (EGF). Surpris- 
ingly, the PRO variant was stimulated by each of the factors 
(Fig. 2, right), while the parental tumor was either inhibited 
or slightly stimulated. It is possible  that a common regula- 
tory mechanism has been mutated in the PRO,  leading to 
upregulation of the mitogenic response to several growth 
factors. 
To determine whether stimulatory cells were attracted to 
the tumor cells,  supernatants of cultured tumor cells were 
tested for chemotactic activity. In repeated experiments, con- 
ditioned media from 4102-PRO had considerably higher levels 
ofchemotactic activity for thioglycolate-elicited I-PEC com- 
pared with conditioned media from 4102-RE (Fig. 3). This 
chemotactic activity was directional, as we could find no evi- 
dence of increased random movement (Fig. 3). We also found 
that small clusters of 4102-PRO tumor cells, present in the 
peritoneal lavage of nude mice 3 d after tumor cell injection, 
attracted in vitro large numbers of T-PEC. This gradient of 
T-PEC was not found surrounding dusters of 4102-RE tumor 
3.5 
Results 
We first compared the growth of the parental 4102-RE  3 
tumor and the 4102-PRO variant in nude mice. Fig.  1 (left)  ~  2.s 
shows that 4102-RE grows much more slowly during the  3 
first 25 d, though the regressor does continue to grow and 
eventually kills nude mice. However, the growth rates in vitro  "6  2 
(Fig. 1, right) were identical in repeated trials, indicating that  ~ 
the 4102-RE and 4102-PRO interact differently with a host  _: 1.s 
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Figure  1.  Growth of 4102-PRO  (O) and 4102-R.E (O) in nude mice 
(left) and in culture (right). 5  x  106 tumor cells were injected subcutane- 
ously into three to four athymic nude mice. 103 tumor cells were cultured 
per well (eight replicates) in 96-well flat-bottom plates. Growth was mea- 
sured on indicated days in eight replicate cultures by the MTT assay (See 
Materials and Methods). 
RE  PRO  ~  RE  PRO 
Figure 2.  Stimuhtion of tumor cells by tumor-induced PEC and defined 
growth factors. In the left panel, 2.5  x  10  s lavaged T-PEC were added 
to the bottom of a transwell plate. 103 tumor cells were plated in the top 
of the transwells  (on a falter of 0.4-#m pore size) and cultured for 4 d 
in triplicate. The top wells were then transferred  to a new plate for an 
MTT assay. Index of stimulation is calculated as the average OD of tumor 
cells in the presence of T-PEC divided by the avenge OD of tumor cells 
with medium alone. Error bars show SEM for triplicate  wells. In the right 
pand, exponentially growing cells were incubated for 12 h with 0.5% 
FCS.  7  x  103 cells were plated per 96 well in the presence or absence 
of growth factors for 30 h. TGF-Bt was at 10 ng/ml, PDGF at 100 ng/ml, 
bFGF at 25 ng/ml, and EGF at 20 ng/ml. All growth factors were pur- 
chased from R&D Systems, Inc. (Minneapolis,  MN). Wells were pulsed 
with 1 #Ci [3H]thymidine;  incorporation was measured  12 h later. Each 
result is the mean for three replicate wells. Index of stimulation is equal 
to the average incorporation in the presence of growth factors/incorpo- 
ration in 0.5% FCS alone. Similar results were found in eight repeated 
experiments. 
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matory cells by the 4102-PRO.  Tumor  o  .-, 
+so  cell-conditioned  medium  (1.5  x  10  +  _  b;  ~  ol  ro 
cells/10  m1/24  h)  was  placed in  the  No Yx 
~  l  i  bottom of modified Boyden chambers. 
2 x  10  s PECs were added to the top of  Anti-Gr-1  [ 
100  the chambers in either fresh CMEM (to 
i  ]  I  test for directional movement)or the same  Anti-NKl.1  ~ 
conditioned  media  as  in  the  bottom 
chamber (to control for random  move-  Control Ab 
~so,  ment). Cells that had migrated through 
the 5-/~m pores of the filter into the lower  Figure  5.  Anti-Gr-1 antibody treatment  results in reduced outgrowth 
chamber were counted. (See Materials and  of 4102-PRO tumor cells recovered from the peritoneal cavity. 200 #1 of 
0  ~  ~o  ~  ~co~  Methods).  The average (_+ SEM) ofsix  anti-Gr-lascites(*0.4mglgG)oranisotypecontrolasciteswasinjected 
Di~on~  Raaaom  fields from duplicate Boyden chambers is  intraperitoneally into athymic nude mice 2 d before tumor challenge. 0.2 
Conditioned  Media  shown,  mg NKI.1 was injected into B6CByF1/J nude mice. 5 x 106 tumor cells 
were injected intraperitoneally into naive or antibody-treated mice. After 
3 d T-PEC were lavaged in 5 ml PBS and resuspended in 12 ml complete 
cells. Experiments are in progress to identify the chemoat-  MEM.  Recovery of liquid was always greater than 97%.  0.5 ml of cell 
tractant(s) responsible fo this difference,  suspension was plated per well ofa 24-wellplate. An MTT assay was done 
If non-T cell inflammatory cells were providing stimula-  after 10 to 12 d in culture.  Methods  were as described in Materials and 
tory factors, then removal of such cells might reduce tumor  Methods.  Data are pooled from two to four experiments  _+  SEM. 
growth in nude mice. The Gr-1 antigen, defined by the RB6- 
8C5 monoclonal antibody, is highly expressed on mature gran-  To measure the effect of anti-Gr-1 treatment on early tumor 
ulocytes, transiently expressed on cells of the monocyte lin-  cell growth independent of vascularization,  4102-PRO tumor 
eage, and absent from mature monocytes or macrophages  cells were recovered after growth in the peritoneal cavity for 
(6-8). Pretreatment of nude mice with the antigranulocyte  only 3 d. Fig. 5 shows that the recovery and subsequent out- 
antibody (anti-Gr-1) resulted in a 94 _+ 6% decrease in gran-  growth of 4102-PRO tumor cells from the peritoneal cavi- 
ulocytes 2 d after treatment as assessed by differential counts  ties of mice were significantly decreased when mice were 
of peripheral blood smears. The subcutaneous growth of the  pretreated with anti-Gr-1. Pretreatment with either an iso- 
PRO variant was significantly decreased by anti-Gr-1 treat-  type control antibody or the anti-NKl.1  antibody had no 
merit given every 3 d, while the growth of the parental RE  effect. We do not know the absolute numbers of tumor cells 
tumor remained virtually unchanged (Fig. 4, left). Treatment  recovered from the peritoneal cavities since the cells tend to 
of B6CByF1/J nude mice with anti-NKl.1 every 3 d did not  form aggregates, which are difficult to break up. Using the 
affect tumor growth (Fig. 4, right),  although spleen cells from  MTT assay allows for reliable quantification of viable tumor 
these mice had a 94% decrease in NK lytic activity against  cells whether in clusters or dispersed. The MTT metabolism 
YAC cells compared with spleens  from nontreated mice.  by nonmalignant PEC in the cultures must be negligible since 
only tumor cells remain viable after the 10 to  12-d culture 
4  Anti-Gr-1  8  Anti-NKl.1  period. It was essential  to determine whether anti-Gr-1 ac- 
Q RE + No rx  1  tually inhibited granulocyte induction in the peritoneal cavity 
/O'~  PRoRE  ++AbNoTx  I ~]  6  after tumor cell challenge.  PEC washed out of naive mice 
~o3  had no detectable neutrophils or eosinophils, 27% lympho- 
cytes, 71% macrophages/monocytes, and 2% basophils.  4 h 
2  4  after injection of tumor cells, '~36% of the PEC were neu- 
trophils.  However, PEC of tumor-injected mice pretreated 
=  1  2  with the anti-GR-1 antibody 2 d earlier had <1%  neutro-  +- 
phils  (little  change was  detected in  the small  number of 
0  5  10  15  20  t3 ~--~-  15  25  basophils  or eosinophils). 
Days 
Figure 4.  Anti-Gr-1 treatment  reduces subcutaneous tumor growth of  Discussion 
the 4102-PRO variant. 5  x  106 tumor cells were injected subcutaneously  Findings  in  this  study strongly  suggest  that  Gr-1 §  cells 
and tumor growth measured as described in Materials and Methods. (Left)  are required  for the rapid growth of the 4102-PRO  variant 
Effect of anti-Gr-1  treatment.  Mice were treated intraperitoneally  with  in vivo. However, it is not clear which cell type(s) is directly 
200 #1 anti-Gr-1 of ascites, every 3 d beginning on the day of s.c. tumor 
cell challenge. Multiple linear regression was used to relate tumor volumes  responsible for the stimulation.  Both granulocytes and mac- 
to treatment variables. Three experiments were analyzed separately. In each  rophages are known to produce growth factors, and both are 
case, treatment significantly decreased tumor growt.h ~  = 0.005, 0.0012,  present in the peritoneal lavage surrounding PRO tumor cell 
and 0.0005, respectively.) (Right) Treatment of B6CByF1/J nude mice with  clusters.  Pretreatment  of mice with  the granulocyte-specific 
anti-NKl.1 had no significant effect on tumor growth. Mice were treated  anti-Gr-1, and not an isotype control antibody, led to a large 
intraperitoneally with 0.2 mg purified NKI.1. For both panels, each line 
represents the average tumor size for three to four mice per experiment  decrease in the number of peritoneal macrophages that could 
_+ SEM.  be induced with thioglycolate (Pekarek, L., unpublished data). 
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showing that neutrophil depletion leads to an inhibition of 
macrophage recruitment (9) or other mononuclear cells in 
delayed-type hypersensitivity (10). Therefore, granulocytes may 
be stimulatory themselves, or may be involved in the recruit- 
ment of other stimulatory cells. Granulocytes have been found 
to produce factors that are chemotactic for macrophages (11). 
In any event, it appears  that the PRO variant attracts host 
leukocytes that in turn provide factors to stimulate tumor 
growth. We do not know if this type of stimulatory loop 
occurs frequently in tumor progression, but we have made 
similar findings for a second randomly selected progressive 
tumor variant that also retains CTL-recognized antigens (data 
not shown), suggesting that this stimulatory loop may not 
be  rare. 
An optimal growth factor environment may play a key role 
in  tumor  progression.  Some tumors may provide factors 
through an autocrine mechanism, while other tumors may 
depend on host  factors.  It  is  known that  certain tumors 
preferentially spread to specific tissues. For example, human 
prostatic cancer most often metastasizes to bone, and two 
prostatic carcinoma cell lines were stimulated by bone marrow- 
conditioned media (12), an effect attributed to transferrin (13). 
Similarly,  human melanomas may be stimulated by factors 
released by normal dermal fibroblasts  (14), and certain mu- 
fine B cell tumors depend on stimulation by specific CD4 + 
T  cells for growth in vivo (15, 16). 
Tumor cells that do not migrate to a more stimulatory 
environment may undergo heritable changes that enable them 
to attract host cells that provide growth factors.  We found 
stimulation of the 4102-PRO variant by several growth factors, 
including TGF-B, which is growth inhibitory to some tumors, 
including the parental 4102-RE, but stimulatory for other 
tumor cells (5).  TGF-B is secreted by I-PEC (Pekarek, L., 
unpublished results) and has been shown to be produced by 
both monocytes and granulocytes (17-19).  We do not know 
if the other factors that stimulated 4102-PRO growth in vitro 
are secreted by the PEC, although PDGF and bFGF have been 
found to be secreted by peritoneal macrophages (20, 21). Gran- 
ulocytes can produce platelet-activating factor (PAF) (22, 23), 
which stimulates platelets to produce TGF-/3 and PDGF (24). 
In addition, PDGF has been shown to induce the expression 
ofMCP-1, a potent monocyte chemoattractant (25-27). Fur- 
thermore, 4102-PRO produces latent TGF-~ (28) which, if 
activated in vivo by macrophages, could stimulate the growth 
of 4102-PRO. Finally, the previously described less-effective 
immunological rejection of 4102-PRO tumor cells embedded 
in syngeneic stroma (29) may be the result of the local growth- 
promoting environment of the stroma. Resolving the local 
mechanism involved in paracrine stimulation of tumor growth 
will be complicated by the fact that not only multiple cell 
types and cytokines but also the extraceUular matrix may con- 
tribute significantly (for review,  see reference 30). 
Several previous experiments have suggested that granulo- 
cytes can have cytocidal activity in vitro and antitumor ac- 
tivity in vivo against murine cancers (7, 31-35) even though 
human cancer cells are remarkably resistant to oxidative cy- 
tolysis (36). However, the granulocytes studied had been in- 
duced by bacteria, chemicals, or recombinant proteins, or by 
cytokines released from gene-transfected tumor cells (7, 31-35). 
By contrast,  naive  granulocytes and macrophages may be 
tumor stimulatory. This is in agreement with our experi- 
ments showing that naive PEC or tumor-induced PEC stimu- 
late 4102-PRO and not the 4102-RE tumor cells, while the 
same PEC suspension is tumoricidal to both the RE and PRO 
tumor cells when first activated by cytokines in vitro (Pekarek, 
L.,  and H.  Schreiber,  unpublished results). Thus, for con- 
trolling  certain  leukocyte-dependent cancers,  the  tumor- 
infiltrating leukocytes must either be activated to become 
tumoricidal, or the naive stimulatory leukocytes must be elim- 
inated.  In agreement with  the latter notion is  our recent 
finding that anti-Gr-1 treatment alone can lead to complete 
tumor rejection in normal mice (rather than the mere growth 
inhibition observed here in nude mice). Granulocytes may, 
therefore, not be required for an effective T cell response in 
this tumor model (Pekarek, L., and H. Schreiber, manuscript 
in preparation). 
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